<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="206507">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400218</url>
  </required_header>
  <id_info>
    <org_study_id>0954A-323</org_study_id>
    <secondary_id>2006_049</secondary_id>
    <nct_id>NCT00400218</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)</brief_title>
  <official_title>Evaluate the Safety and Tolerability of Hyzaar(R) (Losartan 50 Mg/ Hydrochlorothiazide 12.5 Mg) In the Treatment of Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      Evaluate the safety and anti-hypertensive efficacy of hyzaar(R) in patients with mild to
      moderate essential hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure over 12 weeks</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability.</measure>
  </primary_outcome>
  <enrollment type="Actual">62</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is either receiving high blood pressure monotherapy or no treatment

          -  Patient will have reached the legal age by the time enter the study

          -  Patients diagnosed with mild to moderate essential high blood pressure or high blood
             pressure with other conditions such as diabetes or cardiovascular diseases and are
             taking high blood pressure medication (exclude diuretic), but did not meet treatment
             goal

        Exclusion Criteria:

          -  Patient with high levels of uric acid in the blood who has received medications for
             uric acid in the urine within 3 months prior to enrollment

          -  Patients who are hypersensitive to any component of the study medication

          -  Patients who are hypersensitive to other sulfonamide-derived drugs

          -  Patients with anuria (hyzaar(R) is not recommended for patients with hepatic
             impairment or severe renal impairment, creatinine clearance &lt;/= 30 ml/min)

          -  Unstable diabetes (hba1c &gt; 8%), or a change in diabetes medication during study
             treatment. patients with stable diabetes may enter the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>http://www.merck.com/clinical-trials/policies-perspectives.html</url>
    <description>Click here to access a synopsis of the study results.</description>
  </link>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 13, 2016</lastchanged_date>
  <firstreceived_date>November 15, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
